Novartis AG
NOVN | SW
Overview
Corporate Details
- ISIN(s):
- CH0012005267 (+10 more)
- LEI:
- 5493007HIVTX6SY6XD66
- Country:
- Switzerland
- Address:
- LICHTSTR. 35, 4056 BASEL
- Website:
- https://www.novartis.com/
- Sector:
- Health Care
- Industry:
- Pharmaceuticals
Description
Novartis is structured to deliver innovative products, exploit global scale, and respond to new opportunities and risks. Our divisions - Innovative Medicines and Sandoz - are supported by functional organizations with global scale. Innovative Medicines Made up of two business units, Novartis Pharmaceuticals which includes Novartis Gene Therapies, and Novartis Oncology & our Innovative Medicines Division commercializes innovative patented medicines to enhance health outcomes for patients and healthcare professionals. Sandoz Sandoz is a global leader in generic pharmaceuticals and biosimilars that pioneers novel approaches to help people around the world access high-quality medicines.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
Market Cap data is planned for a future update.
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
Chat, Summarize & Extract with AI!
You have of free filing views remaining.
Upgrade for unlimited access.
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2023-08-07 08:30 |
Declaration of Voting Results & Voting Rights Announcements
Obvestilo o spremembi pomembnega deleža družbe Sandoz AG
|
Slovene | 2.2 MB | |
| 2023-08-07 08:30 |
Declaration of Voting Results & Voting Rights Announcements
Obvestilo o spremembi pomembnega deleža družbe Novartis Pharma AG
|
Slovene | 4.4 MB | |
| 2023-08-07 08:30 |
Major Shareholding Notification
Obvestilo o spremembi pomembnega deleža
|
Slovene | 2.4 KB | |
| 2019-10-22 08:00 |
Quarterly Report
Novartis delivered another strong quarter with double digit sales growth and co…
|
English | 138.9 KB | |
| 2019-10-08 08:15 |
Regulatory News Service
Novartis receives FDA approval for Beovu®, offering wet AMD patients vision gai…
|
English | 28.9 KB | |
| 2019-10-02 08:15 |
Regulatory News Service
Novartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing…
|
English | 21.0 KB | |
| 2019-09-29 17:30 |
Regulatory News Service
Novartis Kisqali® delivers consistently superior overall survival – MONALEESA-3…
|
English | 25.3 KB | |
| 2019-09-17 08:15 |
Regulatory News Service
Novartis Cosentyx® positive 16-week PREVENT results advance potential new indic…
|
English | 24.4 KB | |
| 2019-08-30 08:15 |
Regulatory News Service
Novartis ofatumumab demonstrates superiority versus Aubagio® in two head-to-hea…
|
English | 24.4 KB | |
| 2019-07-29 08:00 |
Regulatory News Service
Novartis provides update on Phase III PARAGON-HF trial in heart failure patient…
|
English | 29.7 KB | |
| 2019-07-18 08:00 |
Regulatory News Service
Novartis delivers strong sales, double digit core operating income growth and l…
|
English | 137.7 KB | |
| 2019-07-01 18:30 |
Regulatory News Service
Novartis successfully completes acquisition of Xiidra®, bolstering ophthalmic p…
|
English | 19.0 KB | |
| 2019-06-07 08:00 |
Regulatory News Service
Novartis announces new leader of Pharmaceuticals Business Unit
|
English | 18.1 KB | |
| 2019-04-24 08:00 |
Quarterly Report
Novartis starts 2019 with strong sales and double digit core1 operating income …
|
English | 95.6 KB | |
| 2019-03-27 00:35 |
Regulatory News Service
Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to…
|
English | 27.7 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-04-30 | N/A | Executive member | Sell | None | 1,973,993.83 CHF |
| 2025-03-07 | N/A | Non-Executive member | Buy | None | 160,000.00 CHF |
| 2025-02-11 | N/A | Executive member | Sell | None | 312,203.18 CHF |
| 2025-02-07 | N/A | Executive member | Sell | None | 2,500,278.74 CHF |
| 2025-02-05 | N/A | Executive member | Sell | None | 1,365,687.19 CHF |
| 2025-02-04 | N/A | Executive member | Sell | None | 1,840,201.00 CHF |
| 2025-01-30 | N/A | Executive member | Buy | None | 699,424.74 CHF |
| 2025-01-30 | N/A | Executive member | Buy | None | 698,883.18 CHF |
| 2024-12-19 | N/A | Executive member | Sell | None | 1.00 CHF |
| 2024-11-29 | N/A | Executive member | Sell | None | 167,294.98 CHF |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
ABIVAX | France | ABVX | |
|
Addex Therapeutics Ltd | Switzerland | ADXN | |
|
AegirBio AB | Sweden | AEGIR | |
|
AGRONOMICS LIMITED | Isle of Man | ANIC | |
|
AIREA PLC | United Kingdom | AIEA | |
|
Alkaloid AD | North Macedonia | ALK | |
| Alma Yesodot Ltd. | Israel | KVSR | ||
|
Antibiotice S.A. | Romania | ATB | |
|
Aran Research & Development (1982) Ltd. | Israel | ARAN | |
|
Asarina Pharma AB | Sweden | ASAP |